ABSTRACT
INTRODUCTION: Tumor budding (TB), defined as the presence of individual neoplastic cells or isolated groups of up to 4 cells at the front of tumor invasion, has become an adverse prognostic marker in colorectal cancer (CRC) in recent decades. The prognostic impact of TB in CRC remains not clearly defined and histological methods for its evaluation vary depending on the center. The objective of this study is to investigate the association between TB and CRC, in terms of oncological evolution and pathological stage. METHODS: A retrospective observational study was conducted, including patients undergoing curative oncological surgery for CRC between January 2017 and December 2022. The effects of TB on disease-free survival (DFS) and overall survival (OS) were evaluated according to the Kaplan-Meier curves. RESULTS: In 78 cases TB was described in the pathology report. TB was present in 56 patients (71.8%), divided into the following categories: low grade in 22 (39.3%), intermediate grade in 17 (30.4%) and high grade in 17 (30.4%). The proportion of patients who presented lymph node metastases, lympho-vascular and perineural invasion was significantly higher in patients with TB (26.8% vs 0%, P=.008; 41.1% vs 4.5%, P=.002; 16.1% vs 0% P=.054; respectively). DFS was 86.3% in low-grade TB, 75.3% in intermediate-grade TB, and 70.3% in high-grade TB. Cases with intermediate and high grade were associated with a shorter OS compared to the low grade group (93.7% and 75.4% vs 100% P=.012, respectively). CONCLUSION: These results suggest that TB expression may be a useful risk factor as a prognostic factor for the detection of lymph node metastasis, local recurrence, and distant metastasis in CRC.
ABSTRACT
No disponible
Subject(s)
Humans , Male , Middle Aged , Paget Disease, Extramammary/diagnosis , Anus Neoplasms/diagnosis , Rectal Neoplasms/diagnosis , Paget Disease, Extramammary/therapy , Anus Neoplasms/pathology , Anus Neoplasms/therapy , Rectal Neoplasms/pathology , Rectal Neoplasms/therapy , Adenocarcinoma/diagnosis , Adenocarcinoma/pathology , Viscera/pathologyABSTRACT
We evaluate the 5-year results of a single-centre prospective randomized trial that compared cyclosporine microemulsion (CyA-me) in triple therapy (plus steroids and azathioprine) and Tacrolimus (Tac) in double therapy (plus steroids) for primary immunosuppression. One hundred adult patients undergoing liver transplantation were randomized to receive Tac (n=51) or CyA-me (n=49). Ten patients in group A, and thirty-one patients in group B had their main immunosuppressive agent switched. The switch was much more frequent from CyA-me to Tac (n=31; 62.3%), mainly because of lack of efficacy (n=12; 38.7%). Six of 10 patients were shifted from Tac to CyA-me for side effects. The clinical course of the majority of patients converted from CyA-me to Tac improved clearly after conversion. Donor age and acute rejection (number, severity and rejection free days) had a significative association with lack of efficacy in group B. In these series, the conversion to Tac from CyA-me could be accomplished safely, with an excellent long-term outcome.
Subject(s)
Immunosuppressive Agents/administration & dosage , Liver Transplantation , Liver/physiopathology , Adult , Aged , Azathioprine/administration & dosage , Cyclosporine/administration & dosage , Female , Humans , Male , Middle Aged , Prospective Studies , Tacrolimus/administration & dosageABSTRACT
No disponible
Subject(s)
Humans , Male , Female , Liver Transplantation/methods , Liver Transplantation , Living Donors , Quality of Life , Hepatitis C/epidemiology , Europe/epidemiology , United States/epidemiology , Asia/epidemiology , Cohort Studies , Liver Failure, Acute/complications , Indicators of Morbidity and MortalityABSTRACT
No disponible
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Hepatitis C/diagnosis , Hepatitis C/surgery , Recurrence , Liver Transplantation/methods , Graft Survival , Liver Diseases/complicationsABSTRACT
No disponible
Subject(s)
Humans , Male , Female , Tissue Donors/legislation & jurisprudence , Donor Selection/methods , Heart Arrest/diagnosis , Liver Transplantation/methods , Graft Survival , Myocardial Ischemia/surgery , Heart Arrest/rehabilitation , Heart Arrest/therapyABSTRACT
The significance of human leukocyte antigen (HLA) compatibility and preformed antibodies in liver transplantation remains unclear. The objectives of this study were to evaluate, in a single-center cohort comprising 896 liver transplants, whether the degree of donor-recipient compatibility and preformed antibodies modified graft survival. Univariate Kaplan-Meier analysis demonstrated that donor-recipient HLA compatibility had a marginal impact on allograft survival. As for compatibility at individual antigen loci, 2 mismatches at HLA-A conferred a survival advantage in retransplanted allografts (P = 0.011). HLA-B and HLA-DR loci did not play a significant role in outcome in any pathology. The concordance of results on preformed antibodies detected by complement-dependent cytotoxicity (CDC) and a multiple bead assay (Luminex xMAP) showed a strong correlation between both techniques (P < 0.0001). Both CDC-detected and Luminex-detected antibodies were associated with shorter graft survival within the first year post-transplant (P = 0.01 and P = 0.016, respectively). Positive CDC T crossmatches and Luminex-detected HLA class II antibodies played a significant role in decreasing graft survival (P = 0.043 and P = 0.0019 at 1 year, respectively, and P = 0.005 and P = 0.038 at 5 years, respectively). A correlation was also observed between the presence of preformed Luminex-detected class II or Luminex I and II antibodies and allograft rejection (P = 0.001 and P = 0.042, respectively). In conclusion, although HLA typing is not a prerequisite for transplantation, screening of HLA antibodies with Luminex techniques and CDC crossmatch may be useful in the detection of at-risk patients that could benefit from increased surveillance and tailored therapy following transplantation.
Subject(s)
Blood Group Incompatibility/immunology , Cytotoxicity, Immunologic , Graft Survival/immunology , HLA Antigens/immunology , Liver Transplantation/immunology , Adolescent , Adult , Child , Cohort Studies , Graft Rejection/immunology , Histocompatibility Testing , Humans , Immunosuppressive Agents/therapeutic use , Liver Failure/immunology , Liver Failure/surgery , Retrospective Studies , Transplantation, Homologous/immunologyABSTRACT
No disponible
Subject(s)
Humans , Male , Female , Middle Aged , Aged , Aging , Liver Transplantation/methods , Life Expectancy , Liver Transplantation/statistics & numerical data , Quality of Life , Tertiary Treatment , Postoperative Period , Perioperative Period/methodsABSTRACT
The rich and diverse heritage of the management of vascular injuries in the 45 independent European countries prevents the authors from revealing a uniform picture of the European experience, but some trends are clearly emerging. In countries with a low incidence of penetrating trauma and increasing use of interventional vascular procedures, the proportion of iatrogenic vascular trauma exceeds 40% of all vascular injuries, whereas on other parts of the continent, armed conflicts are still a major cause of vascular trauma. National vascular registries, mostly in the Scandinavian countries, produce useful, nationwide data about vascular trauma and its management but suffer still from inadequate data collection. Despite a relatively low incidence of vascular trauma in most European countries, the results are satisfactory, probably in most cases because of active and early management by surgeons on call, whether with vascular training or not, treating all kinds of vascular surgical emergencies. In some countries, attempts at developing a trauma and emergency surgical specialty, including expertise in the management of vascular injuries, are on their way.
